References
- Moreau P, Facon T, Attal M, . Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731–735.
- Anagnostopoulos A, Aleman A, Ayers G, . Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004;100:2607–2612.
- San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
- Richardson PG, Sonneveld P, Schuster MW, . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
- Harousseau JL, Attal M, Leleu X, . Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:results of an IFM phase II study. Haematologica 2006;91:1498–1505.
- Harousseau JL, Attal M, Avet-Loiseau H, . Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621–4629.
- Berenson JR, Yang HH, Sadler K, . Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937–944.
- Roussel M, Moreau P, Huynh A, . Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32–37.
- Lee SR, Kim SJ, Park Y, . Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010;45:183–187.
- Sharma M, Khan H, Thall PF, . A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012;118:2507–2515.
- Lonial S, Kaufman J, Tighiouart M, . A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma:a dose- and schedule-finding study. Clin Cancer Res 2010;16:5079–5086.
- Thompson PA, Prince HM, Seymour JF, . Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011;46:764–765.
- Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467–1473.
- Dimopoulos MA, Mateos MV, Richardson PG, . Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23–31.
- Kim HJ, Yoon SS, Lee DS, . Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma:results of a phase II trial. Ann Hematol 2012;91:249–256.